Recent evidence suggests that IDH2 variants may exhibit differential response kinetics to intensive chemotherapy, with R172‐mutated AML showing slower blast clearance than R140‐mutated disease [5]. This evidence concerns the gene IDH2 and acute myeloid leukemia.